* Repro Med Systems Inc KRMD.OQ KRMD.O is expected
to show a
rise in quarterly revenue when it reports results on March 2.
* The Chester New York New York-based company is expected
to
report a 49.5% increase in revenue to $6.064 million from $4.06
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Repro Med Systems
Inc is
for a loss of 3 cents per share. For the same quarter last year,
the company reported a loss of 2 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Repro Med
Systems
Inc is $4, about 24.8% above its last closing price
of $3.01.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.03 -0.02 -0.02 Met 14.3
Jun. 30 2021 -0.02 -0.02 -0.03 Missed -50
Mar. 31 2021 -0.01 -0.01 -0.03 Missed -349.8
Dec. 31 2020 -0.02 -0.01 -0.02 Missed -199.8
Sep. 0.02 0.02 0.01 Missed -51.8
30 2020
Jun. 30 2020 0.02 0.02 -0.03 Missed -250
Mar. 31 2020 0.01 0.01 Met 0
Dec. 31 2019 0.01 0.00 Missed -100
This summary was machine generated February 28 at 23:03 GMT.
All figures in US dollars unless otherwise stated